Hovione Scientia Limited

Wavelength Enterprises Ltd

Perrigo Api Ltd.

Gloria Ten Figas

Ana Fernandez Casares

Zita Mendes

Itai Adin

Sonia Krivonos

Constanca Cacela

Revital Ben-Daniel

Alex Weisman

Constança Cacela

Yevgeny Rozenblat

Ana Fernadez Casares

The present invention concerns new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.

Polymorphic forms of minocycline base and processes for their preparation

Described are new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and Form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.

Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.

Ibrutinib solid forms and production process therefor

Growing community of inventors

Amsterdam, Netherlands

Gloria Ten Figas